🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GSK1265744 5 mg tablet

Found 14 matching trials

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

PHASE2

The goal of this clinical study is to learn more about the effects of switc...

Status

Active Not Recruiting

Location

Be Well Medical Center

Start Date

2022-08-16

Trial ID

NCT05502341

Treatments Being Tested

Bictegravir Lenacapavir BIC/LEN FDC Stable Baseline Regimen

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

PHASE2

This study is a Phase IIa, randomized, multi-site, two-arm, double-blinded ...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-03-27

Trial ID

NCT02076178

Treatments Being Tested

744 Tablet 744 LA Injection Placebo Tablet Placebo Injection

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

PHASE2

This study will establish the minimum safety, tolerability and acceptabilit...

Status

Completed

Location

University of Colorado Denver ATN CRS

Start Date

2020-02-19

Trial ID

NCT04692077

Treatments Being Tested

Cabotegravir (CAB) tablet CAB LA Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

PHASE1

This is a single-center, randomized, open-label, 3 parallel treatment study...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-01

Trial ID

NCT01754116

Treatments Being Tested

GSK1265744 30 mg oral Midazolam 3 mg oral + GSK1265744 30mg oral GSK1265744 400 mg (200 nm)GSK1265744 400 mg (1 micro m)GSK1265744 400 mg (5 micro m)

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females

PHASE2

This study will establish the minimum safety, tolerability and acceptabilit...

Status

Completed

Location

Ward 21 CRS

Start Date

2020-11-04

Trial ID

NCT04824131

Treatments Being Tested

Oral cabotegravir (CAB)CAB LA Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

PHASE2

The purpose of this study was to assess the safety, tolerability, antiviral...

Status

Completed

Location

Alabama CRS

Start Date

2019-12-31

Trial ID

NCT03739996

Treatments Being Tested

Oral Cabotegravir (CAB)Nucleoside Reverse Transcriptase Inhibitors (NRTIs)Long-Acting Injectable Cabotegravir (CAB LA)VRC07-523LS Standard of Care (SOC) ART

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

PHASE1

This is an active control, randomized study to investigate the safety, tole...

Status

Completed

Location

GSK Investigational Site

Start Date

2020-07-31

Trial ID

NCT04484337

Treatments Being Tested

Cabotegravir sodium (Oral Lead In)Cabotegravir 400 mg/mL Cabotegravir 200 mg/mL Topical Non-steroidal anti-inflammatory drug (NSAID)Topical steroid Topical NSAID placebo Recombinant human hyaluronidase PH20 (rHuPH20)Topical steroid placebo

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

PHASE2

This study will evaluate the safety and efficacy of the injectable drug cab...

Status

Completed

Location

Alabama CRS

Start Date

2016-12-19

Trial ID

NCT02720094

Treatments Being Tested

Cabotegravir Oral Tablet TDF/FTC tablets Placebo for TDF/FTC tablets Placebo for cabotegravir oral tablet CAB LA Placebo for CAB LA

A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men

PHASE1

The pre-exposure prophylaxis (PrEP) is an important component in the overal...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-04-10

Trial ID

NCT03422172

Treatments Being Tested

Oral CAB CAB LA

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

PHASE3

This study will evaluate the safety and efficacy of the long-acting injecta...

Status

Active Not Recruiting

Location

Gaborone CRS

Start Date

2017-11-07

Trial ID

NCT03164564

Treatments Being Tested

Oral CAB Oral TDF/FTC Placebo for oral CAB Placebo for oral TDF/FTC CAB LA Placebo for CAB LA

Previous Next